BCL2 and breast cancer: Although tumors in the MYC-low ER+ PDX model responded well to navitoclax as a single agent (we note that BCL-2 expression is often reported as enriched in this breast cancer subtype30), combining it with metformin did not offer any added benefit (Supplementary Figure 5F).